376 related articles for article (PubMed ID: 29461566)
1. [Not Available].
Toft E; Rydén M
Lakartidningen; 2018 Feb; 115():. PubMed ID: 29461566
[TBL] [Abstract][Full Text] [Related]
2. [Novel antidiabetic drugs and cardiovascular complications].
Pareek M; Mortensen MB; Løfgren B; Nielsen ML; Olsen MH; Andersen NH
Ugeskr Laeger; 2018 Feb; 180(6):. PubMed ID: 29429477
[TBL] [Abstract][Full Text] [Related]
3. Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis.
Kadowaki T; Yamamoto F; Taneda Y; Naito Y; Clark D; Lund SS; Okamura T; Kaku K
Expert Opin Drug Saf; 2021 Jun; 20(6):707-720. PubMed ID: 33706621
[TBL] [Abstract][Full Text] [Related]
4. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.
Drake T; Landsteiner A; Langsetmo L; MacDonald R; Anthony M; Kalinowski C; Ullman K; Billington CJ; Kaka A; Sultan S; Wilt TJ
Ann Intern Med; 2024 May; 177(5):618-632. PubMed ID: 38639549
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type 2 diabetes: a retrospective cohort analysis.
McCormick TA; Kramer J; Liles EG; Amos Q; Martin JP; Adams JL
BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38719507
[TBL] [Abstract][Full Text] [Related]
6. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.
Libianto R; Davis TM; Ekinci EI
Med J Aust; 2020 Feb; 212(3):133-139. PubMed ID: 31910303
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular safety of therapies for type 2 diabetes.
Gupta P; White WB
Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
[No Abstract] [Full Text] [Related]
9. Opportunities of Antidiabetic Drugs in Cardiovascular Medicine: A Meta-Analysis and Perspectives for Trial Design.
Yan C; Thijs L; Cao Y; Trenson S; Zhang ZY; Janssens S; Staessen JA; Feng YM
Hypertension; 2020 Aug; 76(2):420-431. PubMed ID: 32639887
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
11. Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure.
Packer M
Diabet Med; 2018 Jun; 35(6):707-713. PubMed ID: 29532519
[TBL] [Abstract][Full Text] [Related]
12. New Therapeutic Strategies for Type 2 Diabetes
Yehya A; Sadhu AR
Methodist Debakey Cardiovasc J; 2018; 14(4):281-288. PubMed ID: 30788014
[TBL] [Abstract][Full Text] [Related]
13. Making sense of newer treatment options for type 2 diabetes.
Lee PC; Hare MJL; Bach LA
Intern Med J; 2018 Jul; 48(7):762-769. PubMed ID: 29984503
[TBL] [Abstract][Full Text] [Related]
14. Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients.
Anderson S; Cotiguala L; Tischer S; Park JM; McMurry K
Ann Pharmacother; 2021 Apr; 55(4):496-508. PubMed ID: 32795145
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular safety outcomes of new antidiabetic therapies.
LeBras MH; Barry AR; Koshman SL
Am J Health Syst Pharm; 2017 Jul; 74(13):970-976. PubMed ID: 28483748
[TBL] [Abstract][Full Text] [Related]
16. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
Bonadonna RC; Borghi C; Consoli A; Volpe M
Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
[TBL] [Abstract][Full Text] [Related]
17. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
North EJ; Newman JD
Curr Opin Cardiol; 2019 Nov; 34(6):687-692. PubMed ID: 31436559
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular effects of antidiabetic drugs.
Sørensen AM; Christensen MB
Drugs Today (Barc); 2018 Sep; 54(9):547-559. PubMed ID: 30303495
[TBL] [Abstract][Full Text] [Related]
19. Glucose lowering and the kidney: are all drug classes equal?
Wong MG; Jardine M; Perkovic V
Lancet Diabetes Endocrinol; 2018 Nov; 6(11):835-837. PubMed ID: 30292590
[No Abstract] [Full Text] [Related]
20. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]